AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (six months ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
UFP Technologies grew six-month revenue 9.6% to $328.2M with organic growth of 6.8%, driven by Medical market strength, while gross margin improved to 29.0% despite SG&A cost inflation.
Biggest Revenue Drivers
Products$324.3M+10.1% YoY
Biggest Revenue Drivers
Total revenue: $328.2M+9.6% YoY
Products$324.3M+10.1% YoY
Largest Expense Items
Cost of sales$232.9M+9.0% YoY
Gross margin improved to 29.0% from 28.6%, driven by increased operating efficiencies.
Selling, general & administrative expenses$43.8M+17.0% YoY
Increased headcount and back-office resources ($2.6M), plus share-based compensation ($1.6M), partially due to CEO transition costs.
Margins: Gross margin expanded to 29.0% for H1 2026 from 28.6% in H1 2025, driven by increased operating efficiencies and leverage on organic sales growth. However, SG&A as a percentage of sales increased to 13.3% from 12.5%, reflecting CEO transition costs and higher headcount.
Watch Items from the Filing
Two customers represent 25.5% and 21.5% of H1 2026 revenue; customer concentration risk remains material with potential for reduced orders.
AJR Labor Issue caused significant workforce turnover in 2025, creating operational inefficiencies and training burdens; productivity impact ongoing through H1 2026.
Cyber Incident detected February 14, 2026; stated as immaterial to date but investigation ongoing and could have future material impact.
Tariff refund process launched April 2026; tariff landscape remains dynamic under current administration, creating ongoing uncertainty and potential cost volatility.
Outstanding debt of $117.3M against $150M revolving facility; company in compliance with all covenants and weighted average interest rate at 5.0%.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
About UFP TECHNOLOGIES INC (UFPT): stock profile, AI score and financials
UFP TECHNOLOGIES INC (UFPT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores UFPT at 63.0/100 on a composite quality score built from its SEC filings, placing it at rank #654 of 2,925 stocks — the top 25% of the AI-ranked universe. UFPT scores in the top quartile across balance sheet strength (87.1), revenue growth (83.4). Areas of concern include institutional flow (25.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 45.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), UFP TECHNOLOGIES INC reports quarterly revenue of $174.0M, net income of $20.9M, an operating margin of 16.2%. UFPT trades on the Nasdaq exchange and files with the SEC under CIK 914156. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate UFPT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for UFP TECHNOLOGIES INC directly from SEC EDGAR.